These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12562545)

  • 1. Pharmacoeconomics of lipid-lowering drugs.
    Smith DG
    Curr Atheroscler Rep; 2003 Jan; 5(1):67-72. PubMed ID: 12562545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
    Kessler JM
    Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
    Jackson JD
    Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of cost-effectiveness analyses of lipid-lowering therapies: From the policy-maker's desk to the patient's bedside.
    Kazi DS; Virani SS
    Prog Cardiovasc Dis; 2019; 62(5):406-413. PubMed ID: 31672610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs.
    Schwartz JS
    Am Heart J; 1999 May; 137(5):S97-104. PubMed ID: 10220608
    [No Abstract]   [Full Text] [Related]  

  • 7. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
    Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
    Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors.
    Blumenthal DM; Goldman D; Jena AB
    JAMA Cardiol; 2017 Oct; 2(10):1063-1064. PubMed ID: 28854318
    [No Abstract]   [Full Text] [Related]  

  • 10. The health economics of the treatment of hyperlipidemia and hypertension.
    McMurray J
    Am J Hypertens; 1999 Oct; 12(10 Pt 2):99S-104S. PubMed ID: 10555609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of a medical aid administrator database for costs and utilisation of benefits by patients claiming for lipid-lowering agents.
    Moodley I
    Cardiovasc J S Afr; 2006; 17(3):140-5. PubMed ID: 16807632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
    Suh DC; Griggs SK; Henderson ER; Lee SM; Park T
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):51-69. PubMed ID: 29148854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors.
    Kazi DS; Penko J; Ollendorf DA; Coxson PG; Bibbins-Domingo K
    Ann Intern Med; 2018 Jun; 168(12):896-898. PubMed ID: 29610832
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
    Czernichow S; Knol MJ; Fezeu L; Grobbee DE
    Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
    Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
    Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive, antidiabetic and lipid-lowering treatment frequencies in France in 2010.
    Tuppin P; Ricci-Renaud P; de Peretti C; Fagot-Campagna A; Gastaldi-Menager C; Danchin N; Alla F; Allemand H
    Arch Cardiovasc Dis; 2013 May; 106(5):274-86. PubMed ID: 23769402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful implementation of a guideline program for the rational use of lipid-lowering drugs.
    Stuart ME; Handley MA; Chamberlain MA; Wallach RW; Penna PM; Stergachis A
    HMO Pract; 1991; 5(6):198-204. PubMed ID: 10115851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies.
    Ortendahl JD; Harmon AL; Bentley TGK; Broder MS
    J Med Econ; 2017 Jul; 20(7):767-775. PubMed ID: 28562126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.
    Chapman RH; Ferrufino CP; Kowal SL; Classi P; Roberts CS
    Int J Clin Pract; 2010 Jan; 64(2):169-81. PubMed ID: 20089007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of care for patients treated with lipid-lowering drugs.
    Carlsson A; Borgström F; Stålhammar J; Alemao E; Yin D; Jönsson L
    Pharmacoeconomics; 2004; 22 Suppl 3():25-35. PubMed ID: 15669151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.